Fiera Capital Corp Raises Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Fiera Capital Corp boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 1.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 516,865 shares of the company's stock after acquiring an additional 5,497 shares during the quarter. Fiera Capital Corp owned about 0.53% of Neurocrine Biosciences worth $68,102,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in NBIX. Los Angeles Capital Management LLC boosted its position in Neurocrine Biosciences by 66.0% in the fourth quarter. Los Angeles Capital Management LLC now owns 918,391 shares of the company's stock valued at $121,007,000 after buying an additional 364,986 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of Neurocrine Biosciences by 120.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 584,539 shares of the company's stock valued at $65,761,000 after acquiring an additional 319,564 shares during the last quarter. Westfield Capital Management Co. LP increased its stake in shares of Neurocrine Biosciences by 73.0% in the third quarter. Westfield Capital Management Co. LP now owns 649,292 shares of the company's stock worth $73,045,000 after acquiring an additional 273,952 shares during the period. Jacobs Levy Equity Management Inc. raised its holdings in shares of Neurocrine Biosciences by 59.0% during the third quarter. Jacobs Levy Equity Management Inc. now owns 692,374 shares of the company's stock worth $77,892,000 after purchasing an additional 256,920 shares during the last quarter. Finally, Jennison Associates LLC lifted its position in Neurocrine Biosciences by 86.0% during the third quarter. Jennison Associates LLC now owns 409,475 shares of the company's stock valued at $46,066,000 after purchasing an additional 189,345 shares during the period. Hedge funds and other institutional investors own 92.59% of the company's stock.

Insiders Place Their Bets

In other news, Director Richard F. Pops sold 15,000 shares of the business's stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $132.47, for a total transaction of $1,987,050.00. Following the transaction, the director now owns 29,512 shares of the company's stock, valued at approximately $3,909,454.64. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Neurocrine Biosciences news, Director Richard F. Pops sold 1,700 shares of Neurocrine Biosciences stock in a transaction on Friday, March 8th. The stock was sold at an average price of $140.05, for a total value of $238,085.00. Following the sale, the director now owns 29,512 shares in the company, valued at $4,133,155.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard F. Pops sold 15,000 shares of the company's stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $132.47, for a total value of $1,987,050.00. Following the completion of the transaction, the director now directly owns 29,512 shares in the company, valued at approximately $3,909,454.64. The disclosure for this sale can be found here. Insiders sold 194,664 shares of company stock valued at $26,877,417 in the last three months. 4.30% of the stock is currently owned by insiders.

Neurocrine Biosciences Price Performance

Neurocrine Biosciences stock traded up $0.38 during trading on Friday, reaching $142.29. 641,937 shares of the company were exchanged, compared to its average volume of 830,752. The stock's 50 day simple moving average is $138.50 and its two-hundred day simple moving average is $130.67. The company has a market capitalization of $14.32 billion, a P/E ratio of 39.14 and a beta of 0.28. Neurocrine Biosciences, Inc. has a 52-week low of $89.04 and a 52-week high of $148.37.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on NBIX shares. Cantor Fitzgerald reiterated an "overweight" rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday, April 10th. Guggenheim boosted their price target on Neurocrine Biosciences from $164.00 to $170.00 and gave the company a "buy" rating in a report on Thursday, May 2nd. Canaccord Genuity Group raised their price objective on shares of Neurocrine Biosciences from $154.00 to $164.00 and gave the stock a "buy" rating in a research note on Thursday, May 2nd. StockNews.com lowered shares of Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 2nd. Finally, HC Wainwright increased their price target on shares of Neurocrine Biosciences from $150.00 to $160.00 and gave the stock a "buy" rating in a report on Thursday, May 2nd. Six analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $148.96.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.